Press Releases
Displaying 1 to 1 of 1 files.
2012 Press Releases
Acura Pharmaceuticals Provides Update On Opioid Product Licensed To Pfizer (33.2 KiB) - added January 23, 2012
Displaying 1 to 19 of 19 files.
2011 Press Releases
Acura Pharmaceuticals Announces Third Quarter 2011 Financial Results (73.1 KiB) - added October 31, 2011
Acura Pharmaceuticals Provides An Update On Impede™ Technology (88.7 KiB) - added October 26, 2011
Acura Pharmaceuticals To Present At The BioCentury NewsMakers In The Biotech Industry Conference (89.6 KiB) - added October 18, 2011
Acura Pharmaceuticals Provides Update On Opioid Product Licensed To Pfizer (27.6 KiB) - added October 17, 2011
Acura Pharmaceuticals, Inc. Names J. Bradley Rivet VP of Marketing (80.8 KiB) - added October 3, 2011
Acura Pharmaceuticals Awarded Key U.S. Patent For Abuse Deterrent Drug Formulations (70.0 KiB) - added September 27, 2011
David F. Azad Appointed To Board Of Directors (19.7 KiB) - added July 28, 2011
Acura Pharmaceuticals Reports 2nd Qtr 2011 Financial Results And Product Development Update (34.3 KiB) - added July 28, 2011
Robert Jones Appointed President & CEO And To The Board Of Directors Of Acura Pharmaceuticals, Inc. (20.0 KiB) - added July 11, 2011
Acura Pharmaceuticals, Inc. Announces The Retirement Of William A. Sumner From Board Of Directors (21.4 KiB) - added July 8, 2011
Acura Pharmaceuticals Receives $20 Million Milestone Payment (27.1 KiB) - added July 1, 2011
Pfizer And Acura Announce FDA Approval Of Oxecta™ (oxycodone HCl, USP) CII (134.5 KiB) - added June 20, 2011
Acura Pharmaceuticals, Inc. Announces Notice Of Allowance For Third Aversion® Technology Patent (24.1 KiB) - added June 6, 2011
Acura Pharmaceuticals, Inc. Announces Appointment Of Robert Jones As Interim President & CEO (23.9 KiB) - added May 2, 2011
Acura Pharmaceuticals, Inc. Announces The Passing Of Andrew Reddick, President & CEO (23.4 KiB) - added April 29, 2011
Acura Pharmaceuticals Reports First Quarter 2011 Financial Results And Product Development Update (28.3 KiB) - added April 28, 2011
Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave (23.9 KiB) - added April 25, 2011
Acura Pharmaceuticals Reports Year-End And Fourth Quarter 2010 Financial Results And Product Development Update (31.0 KiB) - added March 1, 2011
ACUROX® Tablets New Drug Application Accepted For Filing With A Priority Review Classification (33.3 KiB) - added February 14, 2011
Displaying 1 to 12 of 12 files.
2010 Press Releases
King Pharmaceuticals and Acura Pharmaceuticals Announce Submission of New Drug Application for ACUROX® Tablets (56.8 KiB) - added December 20, 2010
Acura Pharmaceuticals Reports 3rd Quarter 2010 Financial Results And Product Development Update (39.9 KiB) - added November 2, 2010
Acura Pharmaceuticals Named In Purported Class Action Securities Litigation (50.4 KiB) - added September 13, 2010
Acura Pharmaceuticals Reports Second Quarter 2010 Financial Results (37.9 KiB) - added July 29, 2010
King Pharmaceuticals And Acura Pharmaceuticals Announce Plans To Submit An NDA For Acurox® Tablets Without Niacin (55.6 KiB) - added May 3, 2010
Acura Pharmaceuticals And King Pharmaceuticals Provide Update On FDA Advisory Committee Meeting For Acurox® (57.9 KiB) - added April 22, 2010
Acura Pharmaceuticals Reports First Quarter 2010 Financial Results (29.7 KiB) - added April 21, 2010
FDA Posts Briefing Documents For April 22nd Joint Advisory Committee Meeting On Acurox® (30.5 KiB) - added April 20, 2010
FDA Schedules Joint Advisory Committee Meeting For Acurox® (53.9 KiB) - added March 17, 2010
Acura Pharmaceuticals, Inc. Announces Investigational New Drug Application (23.0 KiB) - added March 15, 2010
Acura Pharmaceuticals & King Pharmaceuticals Announce Positive Top Line Results Of A Clinical Study Assessing Relative Abuse Potential (39.9 KiB) - added March 8, 2010
Acura Pharmaceuticals Reports Year-End & Fourth Quarter 2009 Financial Results (32.5 KiB) - added March 2, 2010
Displaying 1 to 14 of 14 files.
2009 Press Releases
Acura Pharmaceuticals Reports Third Quarter 2009 Financial Results (32.6 KiB) - added October 26, 2009
Acura Pharmaceuticals And King Pharmaceuticals Provide Update On Acurox® NDA (40.7 KiB) - added September 3, 2009
Acura Pharmaceuticals Submits Acurox® Briefing Package To FDA (26.3 KiB) - added August 6, 2009
Acura Pharmaceuticals Reports Second Quarter 2009 Financial Results (32.6 KiB) - added July 30, 2009
Acura and King Receive FDA Complete Response Letter Regarding Acurox® (115.0 KiB) - added July 2, 2009
Acura Pharmaceuticals Receives Preliminary Review Letter From FDA Regarding Acurox® (24.8 KiB) - added June 23, 2009
Acura Pharmaceuticals Reports First Quarter 2009 Financial Results (29.8 KiB) - added May 1, 2009
Excess Oral Doses Of Acurox® Tablets Are Disliked By Subjects With A History Of Opioid Abuse (50.6 KiB) - added May 1, 2009
Acura Pharmaceuticals, Inc. Names Garth Boehm, Ph.D. VP of Modified Release Dosage Form Development (24.3 KiB) - added March 26, 2009
Acura Pharmaceuticals To Present At Cowen And Company Health Care Conference (19.9 KiB) - added March 11, 2009
Acurox® Tablets New Drug Application Accepted For Filing With A Priority Review Classification (44.2 KiB) - added March 3, 2009
Acura Pharmaceuticals Reports Year-End and Fourth Quarter 2008 Financial Results (35.2 KiB) - added March 2, 2009
Acura Pharmaceuticals, Inc. Names Albert W. Brzeczko, Ph.D. VP, Technical Affairs (20.0 KiB) - added February 9, 2009
New Drug Application Submitted for Acurox® Tablets (98.7 KiB) - added January 2, 2009
Displaying 1 to 13 of 13 files.
2008 Press Releases
King Pharmaceuticals Exercises Option To License Fourth Opioid Product From Acura Pharmaceuticals (40.0 KiB) - added December 24, 2008
Acura Pharmaceuticals, Inc. Reports Third Quarter 2008 Financial Results (31.8 KiB) - added October 27, 2008
Acura Pharmaceuticals And King Pharmaceuticals Announce Positive Top Line Results Of Key Clinical Study Assessing Abuse Liability (43.6 KiB) - added October 13, 2008
Acura Pharmaceuticals, Inc. To Present At Natixis Bleichroeder Hidden Gems Conference (19.9 KiB) - added October 10, 2008
Acura Pharmaceuticals, Inc. Announces Return Of President And CEO From Medical Leave (19.7 KiB) - added September 2, 2008
Acura Pharmaceuticals, Inc. Reports Second Quarter 2008 Financial Results (31.3 KiB) - added July 30, 2008
Acura Pharmaceuticals, Inc. Announces Action Regarding Notice Of Allowance Received For Second Aversion® Technology Patent (26.6 KiB) - added July 21, 2008
Acura Pharmaceuticals, Inc. Added To The Russell 3000® Index And The Russell Microcap® Index (27.5 KiB) - added June 30, 2008
Acura Pharmaceuticals, Inc. Receives $5.0 Million Milestone Payment (27.6 KiB) - added June 30, 2008
Acurox™ Tablets Meet Primary Endpoint In Pivotal Phase III Study (51.3 KiB) - added June 17, 2008
Acura Pharmaceuticals, Inc. Announces Notice Of Allowance For Second Aversion® Technology Patent (26.2 KiB) - added June 3, 2008
Acura Pharmaceuticals, Inc. Announces Active IND For Second Opioid Analgesic Product Candidate Using Aversion® Technology (23.5 KiB) - added June 2, 2008
King Pharmaceuticals Exercises Option To License Third Opioid Product Utilizing Acura's Aversion® Technology (42.0 KiB) - added May 27, 2008
